Navigation Links
Nektar Therapeutics Reports First Quarter 2011 Financial Results
Date:4/27/2011

rst quarter ended March 31, 2011 was $36.0 million or $0.33 loss per share as compared to a net loss of $6.1 million or $0.07 loss per share in the first quarter of 2010.

Conference Call to Discuss First Quarter 2011 Financial ResultsNektar management will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT) today, Wednesday, April 27, 2011.

The press release and a live audio-only Webcast of the conference call can be accessed through a link that is posted on the home page and Investor Relations section of the Nektar website: http://www.nektar.com. The web broadcast of the conference call will be available for replay through Wednesday, May 25, 2011.

To access the conference call, follow these instructions:

Dial: (800) 573-4754 (U.S.); (617) 224-4325 (international)

Passcode: 88966725 (Nektar Therapeutics is the host)

An audio replay will also be available shortly following the call through Wednesday, May 25, 2011 and can be accessed by dialing (888) 286-8010 (U.S.); or (617) 801-6888 (international) with a passcode of 92209339.

In the event that any non-GAAP financial measure is discussed on the conference call that is not described in the press release, or explained on the conference call, related information will be made available on the Investor Relations page at the Nektar website as soon as practical after the conclusion of the conference call.

About NektarNektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar has a robust R&D pipeline of potentially high-value therapeutics in oncology, pain and other areas. In the area of pain, Nektar has an exclusive worldwide license agreement with AstraZeneca for NKTR-118, an investigational drug candidate, being evaluated in Phase 3 clinical studies
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Dennis Winger Joins Nektar Therapeutics Board of Directors
2. Nektar Therapeutics Reports Third Quarter 2009 Financial Results
3. Nektar to Announce Financial Results for the Third Quarter of 2009 on Wednesday, November 4, 2009, After Close of U.S.-Based Financial Markets
4. Nektar Therapeutics to Host Conference Call to Discuss Todays Announcement of a New Partnership for NKTR-118 and NKTR-119
5. AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation
6. Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City
7. Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4, 2009, After Close of U.S.-Based Financial Markets
8. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Chief Medical Officer
9. Nektar Therapeutics Reports First Quarter 2009 Financial Results
10. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 29th Annual Cowen and Company Healthcare Conference in Boston
11. Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... OncoTAb, Inc., a University of ... that Pinku Mukherjee, Ph.D. has received the O. ... highest faculty honor. Mukherjee received the award, which recognizes ... innovative research and development of cancer diagnostics and treatments. ... moment in my scientific career,” said Mukherjee, OncoTAb Co-founder ...
(Date:5/1/2015)... SAN DIEGO , May 1, 2015 /PRNewswire/ ... biotechnology company engaged in the development of biosimilar ... proteins, announced today that its first quarter 2015 ... 14, 2015, before the open of market. At 8:30 ... conference call to discuss the financial results and ...
(Date:5/1/2015)... A new report by  visiongain ... reach $22.4bn in 2019. That revenue forecast and others ... Prospects 2015-2025 ,  published in March 2015. ... provide forecasts and qualitative analyses of the antithrombotic drugs ... in London, UK . It produces ...
(Date:5/1/2015)... Albany Molecular Research Inc. (NASDAQ: AMRI ... AMRI,s President and Chief Executive Officer, will present at ... Conference on Wednesday, May 13, 2015 at 4:20 p.m. ... presentation can be accessed at AMRI,s Investor Relations web ... will be archived for 90 days following the live ...
Breaking Biology Technology:OncoTAb CSO Awarded the University of North Carolina’s O. Max Gardner Award 2Pfenex To Report First Quarter 2015 Results and Provide Business Update on Thursday, May 14, 2015 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 4Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 5AMRI to Present at the Bank of America Merrill Lynch 2015 Health Care Conference 2
... April 1 Nutrition 21, Inc. (Nasdaq: ... that help consumers manage blood sugar levels, improve cardiovascular ... today that on March 31, 2009 it redeemed all ... required by the terms of these shares. The Company ...
... and Saint Joseph,s Hospital Team UpATLANTA, April 1 ... have joined together to begin the first regional research ... pancreatic cancer. Tissue and serum samples from patients ... in genetic and cellular features between normal and tumor ...
... to prior yearROCHESTER, N.Y., April 1 VirtualScopics, Inc. ... quantitative imaging for clinical trials, today announced that its ... its active and awarded projects and commonly referred to ... million which compares to $13.7 million at the same ...
Cached Biology Technology:Nutrition 21 Redeems Series I Convertible Preferred Shares 2Nutrition 21 Redeems Series I Convertible Preferred Shares 3Groundbreaking Research Begins for Pancreatic and Lung Cancers 2Groundbreaking Research Begins for Pancreatic and Lung Cancers 3VirtualScopics' Project Balance Exceeds a Record $31 Million 2VirtualScopics' Project Balance Exceeds a Record $31 Million 3
(Date:3/24/2015)... March 24, 2015   NexID Biometrics LLC, ... security-authentication needs, today announced the beginning of shipments of ... The company, based in Potsdam, ... three-day Connect:ID Expo, which began here today at the ... version 2.0 of its SDK boosts the accuracy rate ...
(Date:3/23/2015)... 23, 2015 SoundView Technology Group issues a new ... NXTD ) Wocket smart wallet. SoundView was one of the selected ... experience with the Wocket in multiple scenarios and outlets. ... and other retailers, making both debit and credit card payments.  ... says, "If the company meets their plans in 2015, it ...
(Date:3/23/2015)... ANGELES , March 23, 2015  In the ... Federal fraud case conviction losses. This figure accounts for ... which, according to The Nilson Report, exceeds $11 billion ... investigative tool after a crime has occurred. Investor ... and polygraph expert Joe Paolella partnered to ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... Thirty to fifty percent of the global conversion of nutrients ... of the National Academy of Science of the United States ... state that this conversion is not carried out by denitrifying ... Nitrogen compounds act as fertilizers and are the ecological basis ...
... with variant Creutzfeldt-Jakob (vCJD) prions may no longer be ... a transfusion. Pall Corporation (NYSE: PLL) announced today the ... Prion Reduction Filter System. It is the first and ... the causative agent of vCJD from red cells, the ...
... only three months after deciding to create an ... trial registry and results database using an independent ... trials can be accessed by anyone, anywhere, with ... give patients and healthcare providers ready access to ...
Cached Biology News:Anammox bacteria produce nitrogen gas in oceans' snackbar 2Anammox bacteria produce nitrogen gas in oceans' snackbar 3First technology to remove prions that cause vCJD from blood launched 2First technology to remove prions that cause vCJD from blood launched 3First technology to remove prions that cause vCJD from blood launched 4Roche clinical trial registry and results database launched 2Roche clinical trial registry and results database launched 3
... Immunogen: Synthetic phosphopeptide corresponding to ... Ser603 residue of rat Synapsin ... synapsin I when phosphorylated at ... Rat (positive control: rat brain ...
EMBP (FL-222)...
... does not share significant homology with ... is expressed in the central nervous ... stomach. One important role PEBP ... activity against several serine proteases including ...
Anti-Rsk2/MAPKAP Kinase 1b, #0 SK2/MAPKAP K1 beta Smartpool&t 3T3 cell lysate Non-specific Control Pool , #D 1X Universal Buffer...
Biology Products: